Table 2.
Comparison With Results of Previous Studies
| Variable | EGFR TKI | PFS (Months) | Reference |
|---|---|---|---|
| NEJ002 | Gefitinib | 10.8 | 15 |
| WJOG3405 | Gefitinib | 9.2 | 6 |
| LUX-Lung 7 | Gefitinib | 10.9 | 12 |
| EURTAC | Erlotinib | 9.7 | 7 |
| OPTIMAL | Erlotinib | 13.1 | 9 |
| JO22903 | Erlotinib | 11.8 | 11 |
| LUX-Lung 3 | Afatinib | 11.1 | 8 |
| LUX-Lung 6 | Afatinib | 11.0 | 14 |
| LUX-Lung 3 (Japanese) | Afatinib | 13.8 | 5 |
| LUX-Lung 7 | Afatinib | 11.0 | 12 |
| Present study | Gefitinib | 9.2 | |
| Present study | Erlotinib | 9.8 | |
| Present study | Afatinib | 13.1 |
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PFS, progression-free survival.